Propanc Biopharma (NASDAQ:PPCB) Stock Price Down 5.5% – Here’s Why

Propanc Biopharma Inc (NASDAQ:PPCB)’s share price fell 5.5% during trading on Monday . The stock traded as low as $1.31 and last traded at $1.37. 28,973 shares were traded during mid-day trading, a decline of 55% from the average session volume of 64,605 shares. The stock had previously closed at $1.45.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Propanc Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Propanc Biopharma Price Performance

The firm’s 50-day moving average is $2.32 and its 200 day moving average is $7.64. The stock has a market cap of $3.12 million, a price-to-earnings ratio of -0.06 and a beta of 3.48.

Institutional Trading of Propanc Biopharma

A hedge fund recently bought a new stake in Propanc Biopharma stock. Virtu Financial LLC bought a new position in Propanc Biopharma Inc (NASDAQ:PPCB) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned 0.33% of Propanc Biopharma at the end of the most recent quarter.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.